Open-Label Extension of Other SZ1839 (Iressa) Trials

Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00635973

Enrollment

100

Registered

2008-03-14

Start date

2000-02-29

Completion date

2003-10-31

Last updated

2009-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Iressa, Gefitinib, Cancer, Patients diagnosed with cancer who have previously received Iressa in an Iressa clinical trial

Brief summary

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Interventions

DRUGGefitinib (Iressa)

Iressa

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Received treatment in a previous Iressa clinical trial * Provided Informed Consent to participate in the trial * 30 days or less since completing the previous Iressa trial.

Exclusion criteria

* Radiotherapy completed more than 14 days before starting treatment in this trial * Incomplete healing from prior surgery * Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

Design outcomes

Primary

Measure	Time frame
Adverse Events	Every 28 days

Secondary

Measure	Time frame
Progression Free Survival	Every 28 days
Survival	Every 28 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026